莫雷西嗪对扩张型心肌病室性心律失常远期死亡率的影响  

The effect of moricizie on long-period mortality in dilated cardiomyopathy patients with ventricular arrhythmia

作　　者：张志强[1] 张增堂[1] 陈莉[1] 黄诺[1] 

机构地区：[1]莱芜市人民医院心内科,山东莱芜271100

出　　处：《临床心血管病杂志》2003年第12期733-734,共2页Journal of Clinical Cardiology

摘　　要：目的 :观察莫雷西嗪对扩张型心肌病 (DCM )室性心律失常远期死亡率的影响。方法 :5 0例DCM室性心律失常患者随机分为两组 :常规治疗 (CT)组和莫雷西嗪治疗 (MT)组 ,随访 4年 ,对资料完整的 4 3例 (CTG组 2 1例 ,MTG组 2 2例 )进行分析。结果 :DCM室性心律失常患者经应用雷莫西嗪治疗后近期 (第 1、2年 )能有效地控制心律失常 ,远期 (第 3、4年 )能使心律失常增加 ;4 3例中 ,死亡 14例 ,且 4年死亡率呈逐年增加趋势。结论Objective:To observe the effect of Moricizine on long-period mortality in dilated cardiomyopathy patients with ventricular arrhythma.Methods:Fifty patients of dilated cardiomyopathy with ventricular arrhythmia were randomized into control treatment group (CTG) and Moricizine treament group (MTG). Patients in MTG were given Moricizine treatment while those in CTG given routine treament and followed up 4 years.Results:Forty-three Patients of dilated Cardiomyopathy had entire data (21 patients in CTG, 22 patients in MTG). The number of Ventricular Arrhythmia in MTG was decreased in short period (In the first and the second year) and increase in long period (in the third and the forth year); The Mortality was increased in the 4 year.Conclusion:Miricizine can increase mortality when treating ventricular arrhythmia of dilated cardiomyopathy in long period.

关 键 词：心肌病 扩张型 心律失常 莫雷西嗪 

分 类 号：R542[医药卫生—心血管疾病] R972[医药卫生—内科学]